We are live on
!
Find out more
PAI
Palo Alto Investors Portfolio holdings
AUM
$654M
1-Year Est. Return
77.8%
This Fund
S&P 500
This Quarter
Est. Return
+15.32%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.07B
AUM Growth
+$118M
(+12%)
Cap. Flow
-$32.4M
Cap. Flow
% of AUM
-3.02%
Top 10 Holdings %
Top 10 Hldgs %
72.05%
Holding
37
New
3
Increased
23
Reduced
6
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
KYTH
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
|
+$24.1M |
| 2 |
CBST
CUBIST PHARMACEUTICALS INC
CBST
|
+$20.8M |
| 3 |
ARIA
Ariad Pharmaceuticals Inc
ARIA
|
+$18.6M |
| 4 |
QCOR
QUESTCOR PHARMA INC
QCOR
|
+$18.2M |
| 5 |
NPSP
NPS PHARMACEUTICALS INC
NPSP
|
+$12.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
VPHM
VIROPHARMA INC
VPHM
|
+$125M |
| 2 |
ONXX
ONYX PHARMACEUTICALS INC
ONXX
|
+$42.8M |
| 3 |
SVNT
SAVIENT PHARMACEUTICALS INC
SVNT
|
+$5.46M |
| 4 |
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
|
+$4.17M |
| 5 |
Rigel Pharmaceuticals
RIGL
|
+$3.18M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 44.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Insmed
INSM
$28.9B
| $4.97M | 0.46% |
292,199
+25,900
| +10% | +$397K |
|
|
SPPI
27
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $3.56M | 0.33% |
402,285
+6,300
| +2% | +$56.3K |
|
|
AVEO
28
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| $2.62M | 0.24% |
142,917
-208,004
| -59% | -$4.17M |
|
|
XOMA
29
DELISTED
Xoma
XOMA
| $1.72M | 0.16% |
12,805
-8,104
| -39% | -$817K |
|
30
Cytokinetics
CYTK
$10.5B
| $1.51M | 0.14% |
232,808
-28,736
| -11% | -$189K |
|
|
HPTX
31
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
| $1.27M | 0.12% |
62,700
| – | – |
|
|
SPHS
32
DELISTED
Sophiris Bio, Inc.
SPHS
| $1.08M | 0.1% |
292,900
+237,900
| +433% | +$1.01M |
|
|
CELG
33
DELISTED
Celgene Corp
CELG
| $438K | 0.04% |
5,180
+1,800
| +53% | +$142K |
|
|
NXTM
34
DELISTED
NxStage Medical Inc.
NXTM
| – | – |
-44,129
| Closed | -$581K |
|
|
SVNT
35
DELISTED
SAVIENT PHARMACEUTICALS INC
SVNT
| – | – |
-8,752,981
| Closed | -$5.46M |
|
|
ONXX
36
DELISTED
ONYX PHARMACEUTICALS INC
ONXX
| – | – |
-343,473
| Closed | -$42.8M |
|
Similar funds
AG
BL
PIM
ACA
PCM
HCM
ACM
DC
Palo Alto Investors's Q4 2013 Portfolio in Review
As of Q4 2013, Palo Alto Investors held 37 positions worth $1.07B, up 12% from $954M the previous quarter. Its ten largest holdings account for 72% of the portfolio.
Palo Alto Investors withdrew a net $32.4M in Q4 2013, closing 3 positions and reducing 6 holdings. Its most notable exit was ONYX PHARMACEUTICALS INC, an estimated $42.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 44% of assets, up from 36% a quarter earlier.
Against the trend, Palo Alto Investors opened a new position in Ariad Pharmaceuticals Inc worth $23.5M.
- Palo Alto Investors's largest Q4 2013 buy was Ariad Pharmaceuticals Inc: 3,441,324 shares worth $23.5M.
- Palo Alto Investors added most to KYTHERA BIOPHARMACEUTICALS, INC COM in Q4 2013, an estimated $24.1M increase.
- Palo Alto Investors's biggest Q4 2013 reduction was VIROPHARMA INC, cutting an estimated $125M.
- Palo Alto Investors fully exited ONYX PHARMACEUTICALS INC in Q4 2013, selling an estimated $42.8M.
- Palo Alto Investors's ten largest holdings make up 72% of its $1.07B portfolio in Q4 2013.
- Palo Alto Investors opened 3 new positions and closed 3 in Q4 2013.
- Palo Alto Investors's portfolio value rose 12% quarter-over-quarter to $1.07B.
Based on Palo Alto Investors's 13F filing for Q4 2013, filed 13 Feb 2014.